Martin Greenacre

Europe is a front runner in cutting CO2 emissions. Now it must do more to reap the economic benefits through home-grown production of green technologies, such as electric car batteries and solar panels, that underpin this transition, says research chief Marc Lemaître

It is promised as the most important update for more than twenty years, but tensions are high as MEPs struggle to reach a compromise over the EU’s proposed pharmaceutical reform

The EU has officially launched its Chips joint undertaking, kicking off with a call for four pilot production lines to bridge the gap between research and fabrication

European tech start-up funding is down from $82B in 2022, to $45B in 2023. France Digitale has some suggestions to stop the slide in its manifesto for the 2024 European elections

Commission President Ursula von der Leyen told European Hydrogen Week the scheme will put in a total of €3B to encourage green production methods. That should be a spur for innovation, but the conference heard of concerns about the direction of the EU’s Clean Hydrogen partnership

The country will promote development of a transnational blockchain infrastructure for the storage and management of official documents, minister for digitisation Mathieu Michel tells Science|Business

The landmark pharmaceutical reforms will not be adopted in this mandate, and the opposing views of the two rapporteurs mean the final text may not be ready to hand over to the next parliament, the Science|Business Health innovation conference hears

With Europe’s launchers in crisis, a ‘paradigm shift’ in its relationship with industry will see the agency copy NASA in adopting a new procurement model in which it no longer owns and operates its own space vehicles

The nuclear industry has welcomed European Commission plans for a concerted effort on small modular reactors. A new international consortium plans to demonstrate the technology in Belgium

There is growing pressure on EU policymakers to play a role in promoting the development of psychedelics as medicines. The pharmaceutical regulations reform is an opportunity to incentivise research say MEPs